Zhongyuan Huaxie Completes First Patient Dosing in VUM02 Injection Phase 1 Clinical Trial
Zhongyuan Huaxie announced that its wholly-owned subsidiary, Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., has completed the enrollment and dosing of the first subject in the Phase 1 multiple-dose administration of its VUM02 injection. This drug is being developed for the treatment of moderate to severe acute graft-versus-host disease (GVHD) in patients who have failed hormone therapy. The clinical trial is designed as a Phase 1/2 study for II to IV degree acute GVHD. The first subject in the Phase 1 multiple-dose portion of the trial was enrolled and dosed on July 17, 2026. As of May 2026, the cumulative research and development investment for this project reached 8.3089 million yuan.
The successful enrollment and dosing of the first participant in the VUM02 injection's Phase 1 clinical trial marks a crucial step in the development of a potential new therapy for acute graft-versus-host disease. The company's investment of over 8.3 million yuan highlights the significant resources dedicated to this program. Moving forward, the trial's progression will be closely watched to assess the drug's safety and efficacy profile. The success of such novel treatments is vital for improving outcomes in transplant medicine, where GVHD remains a significant challenge. Future developments will likely focus on demonstrating clear clinical benefits and navigating the complex regulatory pathways for rare or severe disease indications.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.